Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciprofloxacinum hýdróklóríð; hydrocortisonum inn - eyrnadropar, dreifa - 2 mg + 10 mg/ml

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - neomycinum súlfat; polymyxinum b súlfat; dexamethasonum fosfat - augndropar, dreifa

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - rivastigminum inn - forðaplástur - 4,6 mg/24 klst.

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuclide imaging - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - stækkun Æxli, gelding-Þola - heilsueyðandi lyf - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.